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OnabotulinumtoxinA (OnabotA) was approved for treat-
ment of chronic migraine (CM) following the PREEMPT
trials [1,2], and was licensed in Italy in February 2013.
Thus, in December 2013 we began to offer OnabotA to
patients with CM who did not respond to other preven-
tive therapy (mostly topiramate, beta blockers, amitripty-
line and calcium channel antagonists). Demographic and
migraine characteristics of patients were recorded, and
changes in monthly migraine days and headache inten-
sity (the latter variable was evaluated only after the first
session of treatment), as well as, the number of sympto-
matic medications intake, were assessed. From December
2013, 40 patients (9 males, 31 females) were treated with
at least four therapeutic sessions. Their mean age (± SD)
at treatment onset was 51.3±12.6 years (range: 27-80). All
the patients fulfilled the ICHD-III criteria for CM [3] and
28 (70%) were receiving other preventive therapy.
In 34 of these patients (85%) overuse of symptomatic
medications was observed at the onset of treatment.
After obtaining an informed consent, we administered
OnabotA according to the PREEMPT protocol (155 UI
for a total of 31 injections divided across 7 head/neck
muscles), performing no additional injections in the first
session (from the second session we also adopted “follow
the pain” protocol), and we gave the patients a paper
diary to register the headache evolution. After one year
of treatment we analyzed the data related to the
40 patients, observing positive results in all the variables
considered. In particular, following 1-year treatment
there was a reduction from 25.1±6.1 to 19.8±9.1 in the
mean (± SD) number of monthly migraine days (reduc-
tion of 21%, p < 0.0001). The intake of symptomatic med-
ications was reduced of about 12%, but the difference was
not statistically significant. Most (78%) of the patients
(n = 23) who had accurately registered the data reported
that the greatest clinical benefit of OnabotA was the
reduction in the headache intensity. Finally, no severe
adverse event was observed, and mild pain in the injec-
tion site was the most reported experience. No patient
discontinued the treatment because of side effects. We
can conclude that the use of OnabotA according to the
PREEMPT paradigm is an effective and well-tolerated
treatment in patients with chronic migraine in a real-life
setting.
Written informed consent to publication was obtained
from the patient(s).
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